ARS Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Cash & Equivalents	59.56	50.82	70.97	210.52	60.06	24.52
Short-Term Investments	228.65	263.21	157.39	63.86	-	-
Cash & Short-Term Investments	288.21	314.02	228.36	274.38	60.06	24.52
Cash Growth	40.72%	37.51%	-16.77%	356.82%	144.94%	-
Accounts Receivable	36.45	8.18	-	-	-	0.38
Other Receivables	1.24	0.99	0.69	1.01	0	0
Receivables	37.69	9.16	0.69	1.01	0	0.38
Inventory	7.78	5.21	-	-	-	-
Prepaid Expenses	3.83	4.67	2.03	2.31	0.67	1.48
Other Current Assets	1.35	1.23	0.65	-	-	-
Total Current Assets	338.86	334.3	231.73	277.7	60.73	26.38
Property, Plant & Equipment	2.65	1.07	0.82	0.77	0.69	0.02
Other Intangible Assets	14.85	7.69	0.62	-	-	-
Other Long-Term Assets	16.44	8.11	0.02	2.96	0.02	0
Total Assets	372.8	351.15	233.19	281.44	61.45	26.41
Accounts Payable	8.38	14.13	0.76	1.66	1.79	1.22
Accrued Expenses	24.15	4.15	0.36	2.1	1.3	0.84
Current Portion of Long-Term Debt	-	-	-	-	3.48	2.56
Current Portion of Leases	0.58	0.04	0.24	0.23	0.14	-
Current Income Taxes Payable	-	-	-	0.17	-	-
Current Unearned Revenue	0.53	0.56	-	0.28	1.46	3.52
Other Current Liabilities	17.24	4.57	1.04	1	0.02	0.08
Total Current Liabilities	50.88	23.44	2.39	5.44	8.19	8.21
Long-Term Debt	168.27	69.38	-	-	4.93	7.46
Long-Term Leases	0.95	-	0.04	0.25	0.48	-
Long-Term Unearned Revenue	1.27	1.53	-	2.85	3	3.44
Other Long-Term Liabilities	3.78	-	-	-	0.08	0.11
Total Liabilities	225.15	94.36	2.43	8.55	16.68	19.23
Common Stock	0.01	0.01	0.01	0.01	0	0.22
Additional Paid-In Capital	400.93	379.87	362	349.41	10.98	7.74
Retained Earnings	-253.28	-123.31	-131.3	-76.94	-42.26	-22.01
Comprehensive Income & Other	-0.01	0.22	0.05	0.41	-	-
Total Common Equity	147.66	256.8	230.76	272.89	-31.27	-14.05
Shareholders' Equity	147.66	256.8	230.76	272.89	44.77	7.18
Total Liabilities & Equity	372.8	351.15	233.19	281.44	61.45	26.41
Total Debt	169.81	69.43	0.27	0.48	9.03	10.02
Net Cash (Debt)	118.4	244.6	228.09	273.9	51.03	14.5
Net Cash Growth	-42.16%	7.24%	-16.73%	436.74%	251.86%	-
Net Cash Per Share	1.21	2.39	2.40	6.86	1.77	0.72
Filing Date Shares Outstanding	197.7	98.12	96.5	94.4	25.7	20.22
Total Common Shares Outstanding	98.84	97.95	96.41	93.94	25.7	20.22
Working Capital	287.99	310.86	229.34	272.26	52.54	18.17
Book Value Per Share	1.49	2.62	2.39	2.90	-1.22	-0.70
Tangible Book Value	132.8	249.11	230.14	272.89	-31.27	-14.05
Tangible Book Value Per Share	1.34	2.54	2.39	2.90	-1.22	-0.70
Machinery	-	1.21	0.67	0.38	0.09	0.03
Leasehold Improvements	-	0.02	0.02	-	-	-

Updated Nov 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q